Publication - Abstract
Nov 09, 2020
pharmaceutics
December 21, 2017
Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.
Publication - Abstract
Nov 09, 2020
pharmaceutics
Publication - Abstract
Mar 18, 2021
European Journal of Pharmaceutics and Biopharmaceutics
Use of the frit-inlet channel improves MD-AF4 analysis of LNP-RNA.
A robust method for AF4 separation of LNP-RNA has been developed and tested on two different platform.
The method meets all the ISO stan...